Page 46 - கொன்சில்ிும் மூலோபாய தகவல்தொடர்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate |Amryt Pharma plc Announcements | Amryt Pharma plc: Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights

Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights DUBLIN, Ireland, and Boston MA, March 11, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that subscription rights relating to warrants to acquire 283,389 Ordinary Shares (the “Warrants”) have been exercised. In order to satisfy the exercise of the Warrants, the Company on 11 March 2021 issued 283,389 ordinary shares of £0.06 each (“Ordinary Shares”) from treasury. The Warrants were issued in connection with the listing of the Company on the AIM Market of the London Stock Exchange in 2016. Each warrant entitles the warrant holder to exercise subscription rights to subscribe for Ordinary Shares at a subscription price of £1.44 per Ordinary Share.

United kingdomUnited statesCity ofAmber fennellRory nealonHypercholesterolaemia hoStifel ben maddisonDaragh oreillyJohn moreJoe wileyEdward mansfieldDaniel bushTim mccarthyLifesci advisorsCompany secretaryMarket of the london stock exchange

Investegate |Allergy Therapeutics Announcements | Allergy Therapeutics: Pledge of Shares

Investegate announcements from Allergy Therapeutics, Pledge of Shares

United kingdomCity ofSmithkline beechamEmma earlNick wykemanFreddy crossleyManuel llobetPanmure gordonChristina tartagliaRupert deardenLondon stock exchangeStern investor relations incBanco santanderConsilium strategic communicationsAllergy therapeuticsChief executive officer

Investegate |Abingdon Health PLC Announcements | Abingdon Health PLC: Webinar: The role of antibody testing as a companion test to SARS-CoV-2 vaccination

Investegate |Abingdon Health PLC Announcements | Abingdon Health PLC: Webinar: The role of antibody testing as a companion test to SARS-CoV-2 vaccination
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomMatthew nealLindsey nevilleLeigh thomasMark draysonMary jane elliottTara mooreNina garrettLawrences youngWarwick medical schoolGlobal sales of abingdon healthUniversity of birminghamUlster universityAbingdon healthDean for external affairsWarwick cancer research centre

Abingdon Health PLC: Webinar: The role of antibody testing as a companion test to SARS-CoV-2 vaccination

Abingdon Health PLC: Webinar: The role of antibody testing as a companion test to SARS-CoV-2 vaccination
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomLindsey nevilleLeigh thomasMark draysonKostenloser wertpapierhandelMary jane elliottTara mooreNina garrettLawrences youngWarwick medical schoolGlobal sales of abingdon healthUniversity of birminghamUlster universityAbingdon healthDean for external affairsWarwick cancer research centre

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results

Hyloris Pharmaceuticals: Hyloris Reports Full Year 2020 Financial Results On track to fuel the pipeline with =4 new product candidates in 2021 Strong cash position of €64 million year-end to execute ambitious growth plan 14 commercial products expected by 2024 Conference call and Liège, Belgium - 9 March 2021 - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today reports its consolidated financial results and a business update for the year ended 31 December 2020, recent achievements, and an outlook for 2021. Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: I am extremely proud of the significant progress we have made across all areas of our business, which has set a strong foundation to execute our ambitious growth plan. We are committed to changing the lives of patients by applying our knowhow and innovative technol

United statesHong kongUnited kingdomCzech republicRegion flamandeUnited arab emiratesAbuz abyNew zealandAmber fennellVan rompayKensington pharmaBiocapital europeOlivier declercqChris welshMarc foidartMarieke vermeersch